CD8A and neoplasm: For example, Sun et al.96 developed and validated CT-derived radiomic biomarkers related to tumor-infiltrating CD8 T cells in patients included in phase I trials of anti-programmed cell death protein-1 (PD-1) or anti-programmed cell death ligand 1 (PD-L1) monotherapy for solid malignant tumors.